5PSQ-043 Abstract withdrawn

<h3>Background and Importance</h3> Bempedoic acid (BA) is a new lipid-lowering drug funded by the national health system (NHS) for patients with atherosclerotic vascular disease (AVD) or familial hypercholesterolaemia (FH) not controlled with the maximum dose of statin + ezetimibe or with intolerance/contraindication to statin/ezetimibe. <h3>Aim and Objectives</h3> To describe the experience of using BA 1 year after funding by the NHS. <h3>Material and Methods</h3> Retrospective observational descriptive study carried out between September 2023–2024. All AB prescriptions made by hospital specialists were included. Patients with AB prescriptions were tracked by the region’s medical prescription analysis system and demographic, clinical and laboratory variables were collected from medical history. Effectiveness and safety were analysed through clinical follow-up and analytical monitoring. Results were analysed in Stata v17.0. <h3>Results</h3> Forty-five patients with a median age of 71 years (IQR 63–76) were included, being women the 42.7%. The median follow-up time was 4.9 months (IQR 3.6–6.3). Indications for AB were 57.15% AVD and 42.85% FH The 33.33% of patients received AB 180mg + ezetimibe 10mg + atorvastatin/rosuvastatin for suboptimal control of their LDL-C levels with high intensity statin + ezetimibe, 47.62% received AB 180 mg + ezetimibe 10mg for non-tolerance/contraindication to statins despite modification of statin type/dose reduction and 19.05% were treated with AB 180 mg monotherapy for intolerance/contraindication to statin and ezetimibe. 100% patients reduced LDL-C and total cholesterol levels with median reductions of 26.3% (IQR 21.7%-32.5%) and 18.0% (IQR 15.7%-27.7%) respectively. The 70% reduced their triglyceride levels. 100% patients who intensified therapy with AB + statin + ezetimibe reached the therapeutic target (LDL-C&lt;55 mg/mL). 93.3% the statin-intolerant patients reached the target with AB 180 mg + ezetimibe 10mg. Mild hypertransaminemia occurred in 11.11%, 6.66% had mild hyperuricaemia which did not require treatment, 6.66% presented mild hyperCKaemia, 8.88% had slightly increased serum creatinine and 22.22% patients had reduced haemoglobin levels but no case was there anaemia (&lt;14.0 g/dl). <h3>Conclusion and Relevance</h3> In all cases AB lowered plasma LDL-C compared to previous therapy with a median reduction &gt;25%. AB addiction achieved the target in 100% of patients when control was suboptimal despite high-dose statin + ezetimibe and &gt;90% the statin-intolerant patients. AB did not present any adverse effects that would require its suspension. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest